MX2010009820A - 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. - Google Patents
2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.Info
- Publication number
- MX2010009820A MX2010009820A MX2010009820A MX2010009820A MX2010009820A MX 2010009820 A MX2010009820 A MX 2010009820A MX 2010009820 A MX2010009820 A MX 2010009820A MX 2010009820 A MX2010009820 A MX 2010009820A MX 2010009820 A MX2010009820 A MX 2010009820A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- present
- receptor antagonists
- concerned
- aminoquinolines
- Prior art date
Links
- 150000005013 2-aminoquinolines Chemical class 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 108010006590 serotonin 5 receptor Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019430 Motor disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000020595 eating behavior Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a derivados de 2-aminoquinolina como antagonistas del receptor 5-HT5A, a su manufactura, a las composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los compuestos activos de la presente invención son útiles en la prevención y/o tratamiento de la depresión, trastornos de ansiedad, esquizofrenia, trastornos del pánico, agorafobia, fobia social, trastornos obsesivos-compulsivos, trastornos por tensión post-traumática, dolor, trastornos de la memoria, demencia, trastornos de los comportamientos de la alimentación, disfunción sexual, trastornos del sueño, abstinencia del abuso de las drogas, trastornos motrices tales como la enfermedad de Parkinson, trastornos psiquiátricos o trastornos gastrointestinales. En particular, la presente invención está relacionada con los compuestos de la fórmula general (I) en donde R y R son como se describieron aquí.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08152618 | 2008-03-12 | ||
| PCT/EP2009/052484 WO2009112395A1 (en) | 2008-03-12 | 2009-03-03 | 2-aminoquinolines as 5-ht5a receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009820A true MX2010009820A (es) | 2010-10-15 |
Family
ID=40506484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009820A MX2010009820A (es) | 2008-03-12 | 2009-03-03 | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8350028B2 (es) |
| EP (1) | EP2254666A1 (es) |
| JP (1) | JP2011513452A (es) |
| KR (1) | KR20100112199A (es) |
| CN (1) | CN101959557A (es) |
| AU (1) | AU2009224760A1 (es) |
| BR (1) | BRPI0908919A2 (es) |
| CA (1) | CA2716907A1 (es) |
| IL (1) | IL207438A0 (es) |
| MX (1) | MX2010009820A (es) |
| WO (1) | WO2009112395A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010003001A (es) * | 2007-09-27 | 2010-04-01 | Hoffmann La Roche | Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a. |
| AU2009221375A1 (en) * | 2008-03-05 | 2009-09-11 | F. Hoffmann-La Roche Ag | 2-Aminoquinolines |
| JP2011513353A (ja) * | 2008-03-07 | 2011-04-28 | エフ．ホフマン−ラ ロシュ アーゲー | ２−アミノキノリン類 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1450801A4 (en) * | 2001-11-27 | 2010-10-27 | Merck Sharp & Dohme | 2-AMINOQUINOLINE COMPOUNDS |
| WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| DE102004008141A1 (de) * | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| WO2007022946A1 (de) * | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| BRPI0717140A2 (pt) * | 2006-09-28 | 2013-10-22 | Hoffmann La Roche | Derivados de quinolina com propriedades de ligação de 5-ht |
| MX2010003001A (es) * | 2007-09-27 | 2010-04-01 | Hoffmann La Roche | Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a. |
-
2009
- 2009-03-03 WO PCT/EP2009/052484 patent/WO2009112395A1/en active Application Filing
- 2009-03-03 EP EP09720136A patent/EP2254666A1/en not_active Withdrawn
- 2009-03-03 CA CA2716907A patent/CA2716907A1/en not_active Abandoned
- 2009-03-03 BR BRPI0908919-5A patent/BRPI0908919A2/pt not_active IP Right Cessation
- 2009-03-03 CN CN2009801072714A patent/CN101959557A/zh active Pending
- 2009-03-03 AU AU2009224760A patent/AU2009224760A1/en not_active Abandoned
- 2009-03-03 KR KR1020107020276A patent/KR20100112199A/ko not_active Application Discontinuation
- 2009-03-03 JP JP2010550132A patent/JP2011513452A/ja active Pending
- 2009-03-03 MX MX2010009820A patent/MX2010009820A/es unknown
- 2009-03-05 US US12/398,415 patent/US8350028B2/en not_active Expired - Fee Related
-
2010
- 2010-08-05 IL IL207438A patent/IL207438A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101959557A (zh) | 2011-01-26 |
| IL207438A0 (en) | 2010-12-30 |
| WO2009112395A1 (en) | 2009-09-17 |
| BRPI0908919A2 (pt) | 2015-07-28 |
| AU2009224760A1 (en) | 2009-09-17 |
| CA2716907A1 (en) | 2009-09-17 |
| US8350028B2 (en) | 2013-01-08 |
| KR20100112199A (ko) | 2010-10-18 |
| US20090233927A1 (en) | 2009-09-17 |
| EP2254666A1 (en) | 2010-12-01 |
| JP2011513452A (ja) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| WO2008080844A9 (en) | Azaspiro derivatives | |
| WO2007076875A3 (en) | Compounds acting on the serotonin transporter | |
| MX2011011489A (es) | Derivados de isoxazol-piridina. | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
| WO2008077810A3 (en) | Spiro-piperidine derivatives | |
| TW200633986A (en) | Therapeutic agents | |
| MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
| DE602007004881D1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| ATE502026T1 (de) | Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung | |
| WO2010026110A3 (en) | 6-substituted benzoxazines as 5-ht-5a receptor antagonists | |
| UA88634C2 (en) | Quaternized quinuclidine esters | |
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| MX2010008239A (es) | 2-aminoquinolinas. | |
| MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
| IL188115A0 (en) | 8-alkoxy-4-methyl-3,4-dihdro-quinazolin-2- | |
| TW200833696A (en) | Spiro-piperidine derivatives | |
| GB0525069D0 (en) | Organic compounds | |
| NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin |